Aspirin for the prevention of cognitive decline in the elderly: Rationale and design of a neuro-vascular imaging study (ENVIS-ion)

Reid, Christopher M., Storey, Elsdon, Wong, Tien Y., Woods, Robyn, Tonkin, Andrew, Wang, Jie J., Kam, Anthony, Janke, Andrew, Essex, Rowan, Abhayaratna, Walter P., Budge, Marc M. and on behalf of the ASPREE Study Group (2012) Aspirin for the prevention of cognitive decline in the elderly: Rationale and design of a neuro-vascular imaging study (ENVIS-ion). BMC Neurology, 12 3.1-3.9.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Reid, Christopher M.
Storey, Elsdon
Wong, Tien Y.
Woods, Robyn
Tonkin, Andrew
Wang, Jie J.
Kam, Anthony
Janke, Andrew
Essex, Rowan
Abhayaratna, Walter P.
Budge, Marc M.
on behalf of the ASPREE Study Group
Total Author Count Override 11
Title Aspirin for the prevention of cognitive decline in the elderly: Rationale and design of a neuro-vascular imaging study (ENVIS-ion)
Journal name BMC Neurology   Check publisher's open access policy
ISSN 1471-2377
Publication date 2012-02
Sub-type Article (original research)
DOI 10.1186/1471-2377-12-3
Volume 12
Start page 3.1
End page 3.9
Total pages 9
Place of publication London, United Kingdom
Publisher BioMed Central
Collection year 2013
Language eng
Formatted abstract Background: This paper describes the rationale and design of the ENVIS-ion Study, which aims to determine whether low-dose aspirin reduces the development of white matter hyper-intense (WMH) lesions and silent brain infarction (SBI). Additional aims include determining whether a) changes in retinal vascular imaging (RVI) parameters parallel changes in brain magnetic resonance imaging (MRI); b) changes in RVI parameters are observed with aspirin therapy; c) baseline cognitive function correlates with MRI and RVI parameters; d) changes in cognitive function correlate with changes in brain MRI and RVI and e) whether factors such as age, gender or blood pressure influence the above associations.

Methods/Design
: Double-blind, placebo-controlled trial of three years duration set in two Australian academic medical centre outpatient clinics. This study will enrol 600 adults aged 70 years and over with normal cognitive function and without overt cardiovascular disease. Subjects will undergo cognitive testing, brain MRI and RVI at baseline and after 3 years of study treatment. All subjects will be recruited from a 19,000-patient clinical outcome trial conducted in Australia and the United States that will evaluate the effects of aspirin in maintaining disability-free longevity over 5 years. The intervention will be aspirin 100 mg daily versus matching placebo, randomized on a 1:1 basis.

Discussion: This study will improve understanding of the mechanisms at the level of brain and vascular structure that underlie the effects of aspirin on cognitive function. Given the limited access and high cost of MRI, RVI may prove useful as a tool for the identification of individuals at high risk for the development of cerebrovascular disease and cognitive decline.

Trial Registration: clinicaltrials.gov Identifier: NCT01038583
Keyword Retinal microvascular abnormalities
Coronary heart disease
Small Vessel Disease
Secondary prevention
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Article number 3

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2013 Collection
Centre for Advanced Imaging Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Access Statistics: 64 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Mon, 18 Jun 2012, 13:40:27 EST by Sandrine Ducrot on behalf of Centre for Advanced Imaging